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Psoriasis is a common heterogeneous inflammatory
skin disease with a complex pathophysiology and
limited treatment options. Here we performed prote-
omic analyses of human psoriatic epidermis and
found S100A8-S100A9, also called calprotectin, as
the most upregulated proteins, followed by the com-
plement component C3. Both S100A8-S100A9 and
C3 are specifically expressed in lesional psoriatic
skin. S100A9 is shown here to function as a chro-
matin component modulating C3 expression in
mouse and human cells by binding to a region up-
stream of the C3 start site. When S100A9 was genet-
ically deleted in mouse models of skin inflammation,
the psoriasis-like skin disease and inflammation
were strongly attenuated, with a mild immune infil-
trate and decreased amounts of C3. In addition, inhi-
bition of C3 in the mouse model strongly reduced the
inflammatory skin disease. Thus, S100A8-S100A9
can regulate C3 at the nuclear level and present
potential new therapeutic targets for psoriasis.
INTRODUCTION
Psoriasis is a chronic recurrent disabling skin disease that
affects approximately 2% of the population. The prototypic
form of psoriasis is characterized by persistent plaques of
inflamed and scaly skin. The initial trigger(s) leading to the devel-
opment of psoriasis are currently unknown. However, it has been
demonstrated that both the innate and adaptive immune sys-
tems play roles in the pathophysiology of psoriasis (Di Meglio
et al., 2011; Lowes et al., 2007). Several mouse models of psori-
asis, targeting either immune cells or keratinocytes have been
developed, constituting powerful tools to dissect the underlying
molecular mechanisms that trigger aspects of this disease
(Arwert et al., 2012; Wagner et al., 2010). A better understanding
of tumor necrosis factor-a (TNF-a) activation in psoriasis, medi-
ated by the tissue inhibitor of metalloproteinase 3 (TIMP)-3 andImmTNF-a converting enzyme (TACE) pathway, came from the ana-
lyses of the inducible AP-1-dependent psoriasis-like mouse
model (Guinea-Viniegra et al., 2009; Zenz et al., 2005). Constitu-
tive epidermal deletion of Junb and Jun in this model led to
massively increased TNF-a shedding, mediated by reduced
amounts of TIMP-3, which rendered high activity of TACE.
TIMP-3 was shown to be a direct transcriptional target of JunB
and Jun (Guinea-Viniegra et al., 2009). In psoriasis, AP-1 activity
is impaired in lesional skin (Johansen et al., 2004) and JunB
expression is heterogeneous within lesional epidermis (Zenz
et al., 2008).
The calcium-binding proteins S100A7 (Psoriasin), S100A8
(MRP-8), and S100A9 (MRP-14) are located in the psoriasis sus-
ceptibility locus 4 (PSORS4) and are highly expressed at sites of
acute and chronic inflammation (Nacken et al., 2003), including
psoriasis (Guttman-Yassky et al., 2008; Swamy et al., 2010). A
mouse model with switchable overexpression of S100A7 and
S100A15 displayed psoriasis-like symptoms upon stress (Wolf
et al., 2010), indicating that S100A proteins are potential media-
tors of psoriasis. Targeted disruption of S100A8 in mice caused
lethality early in development (Baker et al., 2011). In contrast,
mice lacking S100A9 are viable, fertile, and are overall healthy
with a mild peripheral neutropenia (Hobbs et al., 2003; Manitz
et al., 2003).
S100A9 together with S100A8 forms a heterodimeric complex
(Leukert et al., 2006), termed calprotectin, whose molecular
functions are not well understood. The extracellular function of
S100A8-S100A9 is well documented as being a potent chemo-
attractant in mice and antimicrobial in humans (Nakatsuji and
Gallo, 2011). S100A8 and S100A9 bind to several receptors
including RAGE and CD36 (Gebhardt et al., 2008; van Lent
et al., 2009), thereby affecting downstream signaling through
NF-kB and AP-1 (Gebhardt et al., 2006; Grivennikov et al.,
2010). These proteins were also identified as downstream tar-
gets of NF-kB in carcinogenesis (Ne´meth et al., 2009). The
S100A8-S100A9 complex is expressed in epithelial tissues, as
well as in monocytes and granulocytes (Hobbs et al., 2003). In
the skin, basal amounts of calprotectin are very low, whereas it
is highly expressed during wound healing and in inflammatory
conditions like in psoriasis (Kerkhoff et al., 2012).
Based on an unbiased proteomic analysis of psoriatic epider-
mis, here we showed a functional link between S100A8-S100A9unity 39, 1171–1181, December 12, 2013 ª2013 Elsevier Inc. 1171
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Figure 1. The Epidermal Proteome in
Psoriasis
(A) Top 12 upregulated proteins identified by
iTRAQ in psoriasis (p < 0.05 considered significant).
(B) Depicted are differentially regulated proteins
identified in human psoriatic epidermis linked to
lipid metabolism, immune cell trafficking, and
activation and acute phase response signaling (red,
upregulated; blue, downregulated; black proteins
have been identified, but no significant regulation).
(C) Upregulated inflammatory proteins identified in
the human epidermal proteome (p < 0.05).
(D) Immunohistochemical (IHC) stainings for
S100A8-S100A9 and C3 on biopsies of psoriatic
patients covering nonlesional, perilesional, and
lesional skin (n = 6). Scale bar represents 2,000 mm.
(E) IHC for human S100A8-S100A9 in nonlesional
and lesional skin from psoriatic patients. Scale
bar represents 50 mm. (E; arrow indicates extra-
cellular S100A8-S100A9 staining; n = 10). See also
Figure S1.
Immunity
Calprotectin Controls Complement Expressionand the alternative complement pathway composed of the com-
plement component C3 and the complement factor B (CFB). By
using primary mouse and human keratinocytes and mouse
models for skin inflammation and psoriasis, we showed that
S100A8-S100A9 modulated C3 expression by binding to the
promoter. Loss of S100A8-S100A9 and/or blocking C3 led to
prevention of the psoriasis-like phenotype, which provides
potential therapeutic targets for psoriatic patients.
RESULTS
The Epidermal Proteome in Psoriasis
Psoriasis has a highly complex pathophysiology and it has been
demonstrated that a disturbed interaction between immune cells
and keratinocytes underlies the disease symptoms (Nestle et al.,1172 Immunity 39, 1171–1181, December 12, 2013 ª2013 Elsevier Inc.2009). To identify new therapeutic targets
in the psoriatic epidermis, we analyzed
epidermal samples of lesional and nonle-
sional skin of 19 psoriasis vulgaris pa-
tients (psoriasis area severity index > 15)
by using an unbiased iTRAQ (isobaric
tag for relative and absolute quantitation)
approach. By using this methodology,
1,217 proteins could be identified (see
Figure S1A available online) and 214
of these proteins were significantly differ-
entially regulated in lesional compared
to nonlesional epidermis. S100A8 and
S100A9 were the most upregulated
epidermal proteins in lesional epidermis
(Figure 1A). This upregulation of S100A9
was confirmed by protein immunoblot-
ting (data not shown). Bioinformatic ana-
lyses revealed that more than 11% of
the identified differentially regulated pro-
teins are linked to interleukin-1b (IL-1b)
function (25/214 proteins) (Figure S1B).Moreover, the 214 proteins were sorted according to their
canonical functions and pathways with IPA (Ingenuity Pathways
Analysis). This clustering revealed that three major biological
functions, previously implicated in psoriasis, were altered:
immune cell trafficking and activation, acute phase response,
and lipid metabolism (Figure 1B). The complement factor C3
was identified as being functionally involved in all three of these
biological processes (Acevedo and Hammar, 1989; Basset-
Se´guin et al., 1993; Wyatt et al., 1989). Besides S100A8-
S100A9, the complement factor C3 was within the most
significantly upregulated inflammatory proteins in psoriatic epi-
dermis (Figure 1C). Importantly, RNA analyses of C3 and the
C3-activation partner complement factor B (CFB) and of IL-1b
in psoriatic patient samples revealed consistently increased
concentrations (Figures S1C–S1E). Immunohistochemical (IHC)
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Figure 2. Role of S100A9 in Psoriasis-like
Disease
(A) Differentially regulated proteins sorted accord-
ing to their cellular function in psoriatic and DKO*
samples. Bars represent the different cellular func-
tion; the number of upregulated proteins is shown
in red, and the number of downregulated proteins
within this cellular function is shown in blue.
(B) Top-upregulated proteins in DKO* mice ac-
cording to the top-upregulated proteins identified
by iTRAQ in psoriatic epidermal samples (p < 0.05).
(C) Macroscopic phenotype of DKO* mice (n = 20)
and DKO*-S100a9/ mice (n = 20); arrows indi-
cate scaly plaques on the ear surface. H&E stain-
ing of ear sections 18 days after the last tamoxifen
injection.
(D) S100A9 and S100A8 shown by IHC on mouse
ear sections (scale bars represent 50 mm).
(E) Protein immunoblotting of S100A8 and S100A9
from total ear (n = 10 each). See also Figure S2.
Immunity
Calprotectin Controls Complement Expressionstaining for S100A8-S100A9 with an antibody recognizing the
S100 dimer on biopsies from psoriatic patients covering nonle-
sional, perilesional, and lesional skin showed a specific increase
in perilesional to lesional areas (Figures 1D and 1E). Moreover,
IHC staining for C3 on the same biopsies revealed a similar
expression pattern compared to S100A8-S100A9 (Figures 1D
and 1E), suggesting that both proteins are likely involved in
psoriasis pathophysiology and progression. Double labeling of
S100A8-S100A9 and CD45 and C3 and CD45 identified kerati-
nocytes, and to lesser extent immune cells, as the major source
of S100A8-S100A9 and C3 protein (Figure S1F).
To determine whether the induction of S100A8-S100A9 is able
to activate C3 and CFB expression in a cell-autonomous
manner, we knocked down JUNB and JUN in primary neonatal
human keratinocytes similar to the previously described mouseImmunity 39, 1171–1181, Decells (Zenz et al., 2005). JUNB and JUN
knockdown induced high expression of
S100A8-S100A9 leading to strong upre-
gulation of C3 and a significant increase
in CFB and of IL-1b (Figure S1G). These
results suggest a potential causal link
between S100A8-S100A9-mediated in-
duction and expression of C3 in the devel-
opment of psoriasis.
Differentially regulated proteins identi-
fied in the iTRAQ approach clustered in
psoriasis susceptibility regions (PSORS),
when sorted according to their location
in the human genome (Figure S2A).
Furthermore, JUN (PSORS7), JUNB
(PSORS2), S100A8-S100A9 (PSORS4),
and C3 (PSORS2) are all located in
PSORS, emphasizing a potential causal
link of these proteins in psoriasis
(Figure S2A).
To mechanistically define a possible
molecular link between S100A8-S100A9
and C3, we first employed the previously
described inducible psoriasis-like mousemodel (DKO* for inducible, epidermal double deletion of Junb
and Jun). All mutant mice were maintained on a mixed genetic
background for more than 15 generations, and only littermates
were used as controls. In this mouse model, S100A8 and
S100A9 proteins were upregulated prior to the onset of the
disease symptoms and IL-1b concentrations were also induced
in the diseased epidermis (Guinea-Viniegra et al., 2009;
Schonthaler et al., 2009; Zenz et al., 2005). iTRAQ analysis of
epidermis from DKO* mice was performed as for the human
samples. The comparison of the differentially regulated proteins
(p < 0.05) from psoriasis and the psoriasis-like disease, which
were clustered according to their regulation obtained in the
iTRAQ analysis and their cellular functions, revealed a highly
similar pattern (Figure 2A). This indicates that the impairments in
cellular functions observed in psoriatic epidermis are manifestedcember 12, 2013 ª2013 Elsevier Inc. 1173
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Figure 3. Phenotypic Characterization and
Role of S100A9 after Imiquimod Treatment
(A) IHC on ear sections for keratin 10 and keratin 6
in DKO* and DKO*-S100a9/mice. Scale bar
represents 50 mm.
(B) IL-17A and IL-17F levels and (C) IL-23, IL-23R,
and IL-12p40 levels (n = 4–6 each) in co, DKO*,
S100a9/, DKO*, and DKO*-S100a9/mice.
Error bars represent SD.
(D) IHC for myeloid markers F4/80 and Gr-1. Scale
bar represents 50 mm.
(E) RT-PCR analyses for S100A8-S100A9 RNA
in control and s100a9/ mice after Imiquimod
treatment.
(F) H&E staining of back skin from Imiquimod-
treated control and S100a9/ mice (scale bar
represents 50 mm). RT-PCR analyses for S100A8-
S100A9 RNA in control and S100a9/ mice after
Imiquimod treatment. Error bars represent SD.
Statistical analyses are described in Experimental
Procedures. See also Figure S3.
Immunity
Calprotectin Controls Complement Expressionin the psoriasis-like mouse model. Furthermore, this analysis
identified S100A8-S100A9 within the top three upregulated pro-
teins in mouse epidermis displaying a psoriasis-like phenotype
(Figure 2B).
Role of S100A8-S100A9 in Psoriasis
To functionally analyze the role of S100A8-S100A9 in psoriasis
pathogenesis, we genetically deleted S100a9 in the DKO*
psoriasis-like mouse model (DKO*-S100Aa9/) (Figure S2B).
In the absence of S100a9, a significant improvement of the pso-
riasis-like symptoms was observed (Figure 2C; Figures S2C and
S2D). Macroscopically, scaly plaques on the ears and tails of
triple-knockout mice DKO*-S100a9/ were absent (arrows in
Figure 2C). The skin architecture of ears and tails of DKO*-
S100a9/ mice was almost unaffected with minor hyper- and
parakeratosis, (Figure 2C; data not shown). We have previously
shown that S100A8-S100A9 were rapidly upregulated 3 days
after the last Tam injection in DKO* mice and prior to the onset
of the symptoms (Zenz et al., 2005). When monitoring DKO*-
S100a9/ mice for approximately 1 month after the last injec-
tion, no changes in the phenotype were observed.
Protein immunoblotting and immunohistochemical (IHC) ana-
lyses for epidermal S100A8 and S100A9 showed a strong induc-
tion in DKO* mice (Figures 2D and 2E; data not shown). S100A81174 Immunity 39, 1171–1181, December 12, 2013 ª2013 Elsevier Inc.was not detectable by protein immuno-
blotting, IHC, and selective reaction
monitoring (SRM) mass spectrometry
(MS) analysis in DKO*-S100a9/ mice,
which is in agreement with previous re-
sults (Hobbs et al., 2003) (Figures 2D
and 2E; data not shown).
Proliferation assessed by Ki67 staining
was significantly decreased in the basal
layer of the epidermis of DKO*-
S100a9/ compared to DKO* mice, but
not completely reverted to control levels
(data not shown). Analyses of epidermal
markers for differentiation (keratin 10)and stress response (keratin 6) by IHC (Figure 3A) and RT-PCR
(data not shown) showed that proper epidermal differentiation
had recovered and that the stress response was reduced
thereby reflecting the macroscopically improved phenotype.
Importantly, absence of S100a9 in DKO* mice markedly
decreased amounts of IL-17A, IL-17F, IL-23, IL-23R, and IL-
12p40 (Figures 3B and 3C); Il1b RNA and serum concentrations
were also reduced (Figures S2E and S2F). Congruently, DKO*-
S100a9/ mice displayed a significant reduction of multiple
immune cell types in the skin compared to DKO* mice. This
was evident from IHC staining for F4/80+, Gr-1+, CD4+, and
CD8+ cells and was also reflected in the significantly reduced
numbers of myeloid peroxidase (MPO)+ cells in both epidermal
and dermal samples (Figure 3D; Figures S3A and S3B). Intra-
epidermal T cells, a hallmark of psoriasis observed in skin
biopsies, were also seen in DKO* skin and found reduced in
skin sections from DKO*-S100a9/ mice (data not shown).
This indicates that the immune response, an essential initiator
of psoriasis, is diminished due to the loss of S100A8-S100A9.
In addition, the Imiquimod-induced skin inflammation model
(Palamara et al., 2004; Suzuki et al., 2000; van der Fits et al.,
2009) was used to validate the function of S100A9 in a second
mouse model. Although this model has limitations reflecting
the hallmarks of psoriasis, it does show a strong upregulation
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Figure 4. Contribution of Immune Cells to Psoriasis-like Phenotype
(A) Scheme of experimental procedure for bone marrow transplantation
experiments.
(B) H-E staining on ear sections of the different transplantation groups (n = 3).
IHC staining for S100A9 in the different transplantation groups (n = 3; BM: bone
marrow; scale bars represent 50 mm). See also Figure S4.
Immunity
Calprotectin Controls Complement Expressionof S100A8-S100A9 (Figure 3E). Loss of S100A9 resulted in
reduced epidermal thickening (Figure 3F; data not shown),
demonstrating that S100A8-S100A9 play an important role in
promoting the local inflammatory processes leading to a
psoriasis-like inflammatory phenotype.
Serum analyses of cytokines produced by keratinocytes
and implicated in immune cell recruitment in psoriasis, namely
IL-22, M-CSF, GM-CSF, CCL20 (Tohyama et al., 2009), VEGF,
CCL2, and RANTES, were significantly increased in DKO*
mice (Wagner et al., 2010) (Schonthaler et al., 2009) and
data not shown). A subset of these cytokines—CCL2, RANTES,
and TNFa—was reduced in DKO*-S100a9/mice (Figure S3C).
These results demonstrate the role of S100A8-S100A9 and their
downstream signaling in the amplification of the immune
response to develop the psoriasis-like skin disease.
The importance of both, epidermal, as well as immune cell-
derived, S100A8-S100A9 in triggering the psoriasis-like disease
was analyzed by transplanting S100a9/ bone marrow into
DKO* mice and vice versa (Figure 4; Figure S4). Bone marrow
transplantations were performed 3.5 weeks prior to the induction
of the phenotype to secure engraftment (Figure 4A). S100a9/
bone marrow (BM) was transplanted into Junbfl/fl and Junfl/fl
mice, as well as Junbfl/fl and Junfl/fl BM into S100a9/ mice to
control for side effects of the transplantation procedure. No side
effectswere observed, and themicedid not develop any changes
whencompared to controlmice (Figure 4B). Importantly, chimeric
DKO* mice with transplanted S100a9/ BM displayed reduced
psoriasis-like symptoms (Figure 4; Figure 2C). The phenotype
was not abolished, and chimeric DKO*-S100a9/mice carrying
Junbfl/fl and Junfl/fl BMdid not show strongly increased psoriasis-
like symptoms (Figures 4A and 4B; Figures S4A–S4C). Thus,
S100A8-S100A9 produced by both keratinocytes and immune
cells is required to develop the psoriasis-like disease.ImmComplement Component C3 Is Induced by
S100A8-S100A9
To investigate how S100A8-S100A9 regulate the local immune
response resulting in a psoriasis-like skin disease, we next per-
formed an unbiased iTRAQ quantitative proteomic analysis on
isolated epidermis of controls, S100a9/, DKO*, and DKO*-
S100a9/ mice. This analysis identified 94 proteins (p < 0.05)
that were elevated in the DKO* mice and reverted to control
levels in DKO*-S100a9/ mice. These 94 proteins were sorted
according to their canonical functions and pathways with
IPA. This clustering revealed that immune cell trafficking
and activation, acute phase response, and lipid metabolism
(Figure 5A) were affected as seen in the iTRAQ analysis of pso-
riatic epidermis. The complement factor C3 was found to be
significantly downregulated in DKO*-S100a9/ mice in this
proteomic screening (Figures 5A and 5B). Although the prolyl
4-hydroxylase beta protein (P4HB) was also significantly
affected in DKO*-S100a9/ mice, it could not be linked to the
three biological functions (Figure 5B). These data suggest that
C3 is an essential effector downstream of S100A8-S100A9 in
inflammation.
Consistent with the proteomic analysis, C3 mRNA upregula-
tion was observed in isolated DKO* epidermis, but not in DKO*
S100a9/ mice (Figure 5C). To identify which complement
activation pathway was modulated by loss of S100A8-S100A9,
we analyzed RNA of different components of the complement
activation pathways. Complement factor C1r, for example, re-
mained upregulated in DKO*-S100a9/ epidermis (Figure 5D).
However, complement factor B (CFB), an activator of C3 in
the alternative complement pathway, was regulated similarly
to C3 (Figure 5D). CFB associates with C3 to form the C3
convertase, cleaving C3 molecules into C3a and C3b subunits,
thereby activating and enhancing the pathway (Markiewski and
Lambris, 2007). Protein immunoblot analysis of epidermal ex-
tracts of DKO* mice revealed a change in the band pattern of
C3, indicating its cleavage and activation (Figure S5A). A signi-
ficant increase in C3b specific peptides in DKO* epidermis
compared to controls was also detected in the proteomic ana-
lysis, providing further evidence for C3 activation (Figure S5B).
Thus, S100A8-S100A9 is an effective regulator of C3 in skin
inflammation.
The S100A8-S100A9, C3, Axis in Keratinocytes In Vitro
To analyze whether S100A8-S100A9 and C3 function cell
autonomously in keratinocytes, we induced upregulation of
S100A8-S100A9 in primary mouse keratinocytes by deleting
Junb and Jun by using adenoviruses expressing Cre recombi-
nase (Ad-Cre) (DKO) (Figure 5E; Figure S5C). High amounts of
S100A8-S100A9 in DKO keratinocytes were accompanied by
increased C3 and CFB levels (Figures 5F and 5G; Figures S5D
and S5E), whereas C1r levels remained unaltered (Figure S5F).
IL-1b concentrations were elevated along with enhanced
Caspase-1 activity (Figures S5G and S5I). Increased amounts
of IL-1b protein were also detected by ELISA in DKO cell cul-
ture supernatants (Figure S5H). Importantly, DKO-S100a9/
keratinocytes showed significantly reduced amounts of RANTES
and CCL2 (Figure S5J), two known downstream effectors of
C3 (Markiewski and Lambris, 2007; Monsinjon et al., 2003; Ven-
katesha et al., 2005). Moreover, primary keratinocytes treatedunity 39, 1171–1181, December 12, 2013 ª2013 Elsevier Inc. 1175
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Figure 5. Identification of Downstream Effectors of S100A8-S100A9
(A) iTRAQ analysis: differentially regulated proteins in DKO*-S100a9/ mice compared to DKO*, linked to immune cell trafficking and activation, acute phase
response signaling, and lipid metabolism (upregulated proteins in red, downregulated proteins in blue; proteins in black were identified, but not significantly
regulated).
(B) Significantly downregulated inflammatory response proteins in DKO*-S100a9/ compared to DKO* (*p < 0.05) identified by iTRAQ. RT-PCR analysis of C3 (C)
(n = 4–6 each), CFB, C1r (n = 4–6 each).
(D) RNA amounts in ear and tail epidermis of controls, S100a9/, DKO*, and DKO*-S100a9/ mice. Error bars represent SD.
(E) Protein immunoblotting for Jun and JunB in primary mouse keratinocytes after Adeno-cre (Ad-cre) treatment (n = 5).
(F and G) RT-PCR analysis of C3 (F) and CFB (G) after Adeno-cre-mediated (Ad-cre) knockout of Jun and Junb (DKO) in culturedmouse keratinocytes in controls,
S100a9/, DKO*, and DKO*-S100a9/ (n = 4). Error bars represent SD. See also Figure S5.
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Calprotectin Controls Complement Expressionwith lipopolysaccharide (LPS) or flagellin displayed induced
S100A8-S100A9 expression (Abtin et al., 2010; Javkhlan et al.,
2011) and increased amounts of C3 and IL-1b (data not shown).1176 Immunity 39, 1171–1181, December 12, 2013 ª2013 Elsevier InThese data indicate that expression of S100A8-S100A9 and C3-
CFB is regulated in a cell-autonomous manner in keratinocytes,
strongly suggesting an important role in psoriasis.c.
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Figure 6. S100A9 as a Chromatin Compo-
nent Modulating C3 Gene Expression
(A) IHC staining for S100A9 in ear samples of con-
trols, DKO*, and DKO*-S100a9/mice (n = 10).
(B) Confocal analysis of IF staining for S100A9 in
cultured human keratinocytes following TPA-
stimulation for 3 hr (n = 3). Quantification of cells
showing strong nuclear staining due to TPA
treatment (12 randomly chosen fields and treat-
ment) is shown. Error bars represent SD.
(C) Protein immunoblotting for RAD21/cohesin,
Histone H3 (H3), S100A9, and GAPDH in cellular
fractions of cultured mouse keratinocytes after
Ad-cre deletion of Jun and Junb (DKO) and control
cells (co); T, total cell extract; C, cytoplasmic
fraction; sN, soluble nuclear fraction; N, chromatin
enriched fraction (n = 4).
(D) Chromatin immunoprecipitation (ChIP) anal-
ysis for S100A9 on the C3 promoter region iden-
tified binding of S00A9 to an approximately 900 bp
fragment upstream of the C3 translational start
site (pp 9, primer pair 9; pp 5, primer pair 5; n = 4).
Agarose gel electrophoresis pictures of the pp 9
amplicon showing a positive signal and pp 5
showing no binding of S100A9.
(E) Protein immunoblotting of Histone H3, GAPDH,
S100A8, and S100A9 with nucleosome extracts
fromTPAstimulated primarymouse keratinocytes.
As control, cytoplasmic fractions of the same
cells were used; A, mono-nucleosome fraction; B,
mono- and dinucleosome fraction (n = 6). See also
Figure S6, Table S1, S2, and S4; Table S3.
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Numerous reports describe the potential extracellular functions
of S100A9/A8, although a nuclear function inferred from nuclear
staining in different cell lines and psoriatic skin has not yet been
reported (Barbe et al., 2008; Robinson and Hogg, 2000). IHC
staining of highly inflamed mouse skin revealed strong nuclear
localization of S100A9 in DKO* mice (Figure 6A). Moreover,
confocal analysis of IF staining in human primary keratinocytes
treated with TPA revealed a strong increase in nuclear compared
to cytoplasmic S100A9 (Figure 6B). To further investigate the
nuclear localization of S100A8-S100A9, we performed stepwise
cellular fractionations. A strong increase in S100A9 in the nuclear
fraction enriched for chromatin was seen in in vitro deleted DKOImmunity 39, 1171–1181, Dekeratinocytes (Figure 6C). GAPDH was
used as a marker for the cytoplasmic
fraction and histone H3 and Rad21 as
a marker for the chromatin fraction,
showing a clean separation of the subcel-
lular fractions (Figure 6C). These data
suggest that S100A9 can be localized in
the nucleus upon inflammatory stimuli.
To investigate whether the S100A9-
dependent increase of C3 in DKO*
epidermal samples, as well as in vitro-
deleted DKO keratinocytes, was due to
binding of S100A9 to DNA, we performed
a chromatin immunoprecipitation (ChIP)
for S100A9 by using in vitro-deletedDKO cells and DKO-S100a9/ cells as controls (Figure 6D).
Screening of a 5 kb upstream region, which was divided into
approximately 500 bp fragments of the C3 promoter by ChIP
analyses showed consistent binding of S100A9 to an approxi-
mately 900 bp fragment located 2,922 bp upstream of the
ATG-start codon of the C3 gene (primer pairs 8 and 9 in Fig-
ure 6D; Figure S6A; Table S1). Neighboring regions did not
show binding of S100A9 (primer pair 5, Figure 6D). Comparing
the C3 promoter regions on human chromosome 19 and mouse
chromosome 17 revealed a comparable composition. The
approximately 900 bp fragment identified by ChIP for S100A9
is located almost the same distance to the C3 start site in human
and mouse, approximately 2.8 kb and 2.6 kb, respectively.cember 12, 2013 ª2013 Elsevier Inc. 1177
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Figure 7. Downregulation of C3 Attenuates the Psoriasis-like
Phenotype
(A) Experimental procedure blocking C3 with lentivirus-delivered shRNA
against C3 and lentiviruses delivering GFP and scrambled RNAs as controls.
(B) Blocking C3 by intradermal injection of lentiviral shRNAs targeting C3
(sh-C3) into DKO* mice, displaying disease symptoms (n = 5), reduced the
psoriasis-like phenotype compared to lentiviral scrambled RNA-injected
(sh-sc) (n = 3) mice. H&E staining on ear sections of sh-sc and sh-C3 injected
mice. Scale bar represents 50 mm.
(C and D) Analysis of C3 RNA and protein levels by RT-PCR and Selective
Reaction Monitoring (SRM), respectively in extracts from total ear of
scrambled- and shC3-injected mice. Error bars represent SD.
(E) A SRM MS analysis of S100A9 protein in scrambled- and shC3-injected
mice.
(F) Analysis of the epidermal compartment in sh-sc and sh-C3 injectedmice by
IHC staining for keratin 6 (K6), keratin 10 (K10), and Ki67; scale bar represents
100 mm. See also Figure S7.
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Calprotectin Controls Complement ExpressionFurthermore, the 909 bp DNA fragment in the mouse C3 pro-
moter region is highly similar to human (overall approximately
49.9% homology). It contains a sequence of a 153 bp subfrag-
ment, which shows an even higher homology (75%) between
the human and mouse C3 promoter region (Figures S6A and
S6B). Preliminary data from ChIP analyses on human keratino-1178 Immunity 39, 1171–1181, December 12, 2013 ª2013 Elsevier Incytes also suggest binding of S100A9 to the human C3 promoter
(data not shown).
To better define a putative function of S100A8-S100A9 in the
nucleus, we performed immunoprecipitations (IPs) by using an
antibody recognizing the heterodimer S100A8-S100A9 in mouse
keratinocytes stimulated with TPA. The proteins obtained in the
IP were analyzed byMS and the results were evaluated with IPA.
This analysis identified a network of nuclear proteins including
histones (Figure S6C; Table S2). We next isolated nucleosomes
from cells treated with TPA to confirm binding of S100A8-
S100A9 to histones. Mono- and dinucleosome fractions were
analyzed by MS (Figure 6E; Figure S6C; Table S3). Importantly,
S100A8-S100A9 was identified in the mono- and dinucleosome
extracts by protein immunoblotting and by MS analyses (Fig-
ure S6C; Table S4). These results demonstrate a nuclear function
of S100A9 possibly mediated by binding of S100A9 to histones
and thereby regulating or influencing gene transcription.
Blocking C3 Is Therapeutically Beneficial
To investigate the potentially causal role of C3 in psoriasis, we
subcutaneously injected lentivirus-delivered shRNAs targeting
C3 8–10 days after initiating the disease, a time point at which
the psoriasis-like phenotype is clearly visible (Figure 7A). To vali-
date the efficacy of the lentiviral shRNA delivery in the mouse ear
upon subcutaneous injections and to test for side effects, we also
injected mice with lentiviruses expressing GFP or scrambled
shRNA. A clear expression of GFP after lentiviral injection was
seen both in controls and in DKO* mice (Figure S7A). No obvious
side effects due to virus injections were observed (Figure S7B).
Importantly, the psoriasis-like phenotypewas virtually abolished,
when C3 was knocked down in DKO* mice by injecting lentivi-
ruses expressing shRNAs targeting C3 into the ear (Figure 7B).
Only a slight thickening of the epidermis remained visible
(Figure 7B), and C3 RNA and protein levels detected by SRM
analysis were reduced in ears of lenti-shC3 injected mice
compared to scramble controls (Figures 7C and 7D; data not
shown). In contrast, CFB did not show a significant reduction in
sh-C3 treated mice (Figure S7C). Protein levels of S100A8-
S100A9 remained upregulated in sh-C3 treated DKO* mice (Fig-
ure 7E; Figure S7D), whereas RNA levels seemed to be reduced,
although still increased in total ear of sh-C3 injected mice (Fig-
ure S7E). The observed decrease is likely due to reduced
numbers of immune cells in these ears or reflects a feedback
mechanism, which is inhibited by sh-C3 treatment. IHC analyses
for keratin 6 and 10 asmarkers for stress response and epidermal
differentiation showed reduced expression of K6 and amoderate
improvement of K10 (Figure 7F). Ki67-positive cells in the basal
epidermal layer of shC3-injected ears were reduced, but not
completely normalized, reflecting the persisting epidermal thick-
ening (Figure 7F). RNA expression of RANTES and CCL2, both
C3 effectors, were strongly reduced in total ear of shC3-injected
mice (Figures S7F and S7G). These data indicate that C3 plays
a critical role in the psoriasis-like disease and that blocking C3
in psoriasis might be therapeutically beneficial.
DISCUSSION
Unbiased proteomic screening of the epidermal compartments
from psoriatic patients and from genetic mouse models ofc.
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Calprotectin Controls Complement Expressionpsoriasis have allowed us to identify a heretofore unappreciated
functional link between S100A8-S100A9 and the alternative
complement pathway C3-CFB. A remarkably similar protein
expression pattern between diseased patient samples and
epidermal mouse samples was observed, including a strong
upregulation of S100A8-S100A9, IL-1b, and C3. Here we show
that genetic deletion of S100A9 in the psoriasis-like mouse
model reduced expression of complement factor C3 and its
activation partner CFB, as well as IL-1b, thereby preventing the
psoriasis-like disease. Moreover, a yet unknown chromatin
association of S100A9 to the C3 promoter region was discov-
ered in our study. Furthermore, blocking C3 in a mouse model
attenuated the psoriasis-like phenotype.
Increased levels of S100A8-S100A9 in the psoriasis-like
mouse model, as well as in keratinocytes, can be induced by
epidermal deletion of Junb and Jun in vivo and in vitro. Loss of
S100A8-S100A9 leads to prevention of the psoriasis-like symp-
toms, suggesting that this upregulation is a possible trigger for
disease initiation. We propose that the changes in gene expres-
sion convert the keratinocytes into a ‘‘primed’’ state, being more
sensitive to external stimuli, e.g., changes in skinmicroflora (Wolf
et al., 2010; Wolf et al., 2011), facilitating the cellular increase of
C3 in keratinocytes, and thereby activation of immune cells.
Together C3 and CFB form the alternative complement pathway,
which can be activated spontaneously by proteolysis, so called
‘‘tick-over’’ (Bexborn et al., 2008), or by bacterial surface anti-
gens. Proteolytic activation of C3 occurs at low levels; if, how-
ever, C3 and CFB levels in keratinocytes are kept high due to
upregulated S100A8-S100A9, tick-over events increase, leading
to an imbalance in complement surveillance.
Both C3 and CFB belong to the complement network, which
acts as an immune surveillance system able to discriminate
healthy host tissue, cellular debris, and foreign pathogens. It
has become apparent that any stimulus that affects the balance
between complement activation and repression can cause
inflammation and autoimmunity (Markiewski and Lambris,
2007). Keratinocytes are one of few cell types in the body that
can produce S100A8-S100A9 and the complement factors C3
and CFB, making them potent activators of immune cells.
Various insults like a barrier breakdown and bacterial invasion
can lead to increased levels of these factors, signaling to the
immune system that an immediate response is needed. Acti-
vated immune cells are effective producers of S100A8-S100A9
and C3, which in turn will amplify the signal dramatically and
tissue levels of these factors can increase drastically. Several
factors, including IL-17 produced by immune cells, will activate
keratinocytes consequently leading to an autoamplification
loop, which subsequently results in a chronic inflammatory state,
as observed in diseases such as psoriasis.
The secretion of S100A8-S100A9 andC3 by keratinocytes and
binding to their corresponding receptors, e.g., RAGE (damage
associated molecular pattern molecules)-receptors or CD11b,
on infiltrating immune cells stimulates these to produce addi-
tional inflammatory cytokines, like IL-17, MCP-1, and RANTES.
We propose that induction of C3 by S100A8-S100A9 can lead
to ‘‘primed’’ keratinocytes and subsequently to uncontrolled
immune cell activation, angiogenesis, hyperproliferation of kera-
tinocytes, and finally to the chronic inflammation that typifies
psoriasis. Importantly, blocking C3 in the psoriasis-like mouseImmmodel diminished the psoriasis-like symptoms, implying that
S100A8-S100A9 and C3 are not only serum markers for psoria-
sis severity, but likely serve as important amplifiers in psoriasis
pathophysiology.
Until now S100A8-S100A9 proteins are mainly considered as
chemoattractant proteins in mouse and antimicrobial in human.
Our findings show that these proteins can be found in the chro-
matin enriched fraction in keratinocytes and can be implicated
as modifiers of C3 transcription. It is not yet known how these
proteins enter the nucleus, because no nuclear localization
signal has been reported (Vogl et al., 2006). This is particularly
interesting in the context of inflammatory stimuli, which induce
besides a total increase of S100A9 a strong nuclear increase in
primary keratinocytes. Our data indicate that the effect of
S100A8-S100A9 on transcription is not achieved as a classical
transcription factor, but rather through chromatin binding and
remodeling. We show that S100A8-S100A9 proteins can interact
in the nucleus with histones and nucleosomes, thereby possibly
inducing epigenetic changes in gene expression. Future work
will explore this activity of S100A8-S100A9 as well as whether
these findings are applicable to other S100 proteins and other
cell types, such as neutrophils.
Within the last decade, ‘‘biological therapies’’ have proven to
be effective new treatments for inflammatory diseases. However,
a concern about these treatments is the side effects of long-term
chronic immune suppression, involving the potential to increase
the risk of infection and cancer. Hence, development of effective
drugs without these side effects that could be applied locally
would be beneficial for psoriatic patients. As S100a9/ mice
are viable and show no skin phenotype, blocking S100A9 in pso-
riatic patientsmight be beneficial without impairing skin function.
Interestingly, immunoglobulin-based drugs, which function as a
sink for complement components, including C3 (Dalakas, 2004;
Lutz et al., 2004), have emerged as effective long-term therapies
in patients with autoimmune disease (Bayry et al., 2007). Case
reports have shown that targeting C3 can also be beneficial for
psoriatic patients (Gurmin et al., 2002). Moreover, a successful
therapy for age-related macular degeneration (AMD) employed
a C3 inhibitory peptide, which was locally injected into the retina
(Ricklin and Lambris, 2008). This C3 inhibitory peptide is unfortu-
nately not active in rodents (Ricklin andLambris, 2008) and hence
cannot be evaluated in mouse models. Blocking the C3 receptor
CD11b has also been shown to reduce inflammation in a T cell-
dependent inflammation mouse model, supporting the notion
that blocking C3 could be beneficial for psoriatic patients (Leon
et al., 2006). The fact that C3 and CFB have an extracellular func-
tion and are activated locally makes them attractive targets. The
activation of the complement system, being a potent activator of
the blood coagulation or fibrinolysis regulatory cascade, might
also explain the local and precise borders of the inflammatory
plaques, seen in psoriasis. In conclusion, inhibitory strategies
for S100A8-S100A9 and/or C3 have exciting potential to become
effective new therapeutics for psoriasis.EXPERIMENTAL PROCEDURES
Mouse Strains and Treatment
Mice carrying Junb and Jun alleles flanked by loxP sites and the K5-CreERT
allele were used in this study (Zenz et al., 2005). The S100a9/ mouse strainunity 39, 1171–1181, December 12, 2013 ª2013 Elsevier Inc. 1179
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Calprotectin Controls Complement Expressionwas obtained from Nancy Hogg (Hobbs et al., 2003). Eight-week-old mice
were treated with Tamoxifen (1 mg/day) for 5 consecutive days by intraperito-
neal injections with 1 mg tamoxifen (Sigma) to induce the deletion of the two
genes in the epidermis (these mice are referred to as DKO*). All mice were
on a mixed genetic background originally derived from F1 (129/BL/6)
intercrosses for an extensive period of time (over 6 years) with a very robust
and stable phenotype; only littermate controls were used. Controls (Junbf/f;
Junf/f; S100a9+/), S100a9/ (Junbf/f; Junf/f; S100a9/), DKO* (JunBDep/Dep;
JunDep/Dep; S100a9+/+ or JunbDep/Dep; JunDep/Dep; S100a9+/) and DKO*-
S100a9/ (JunbDep/Dep; JunDep/Dep; S100a9/). All mouse experiments
were performed in accordance with local and institutional regulations and
licenses.
Statistical Analysis
Data are shown as mean + SD and were analyzed with a two-sided, unpaired
Student’s t test. Differences were considered statistically significant when p* <
0.05 and the asterisk indicate *p < 0.05; **p < 0.005; ***p < 0.0005.
Imiquimod Treatment
Nine- to 11-week-old S100a9/ mice and control siblings received a daily
topical dose of 50mg of commercially available Imiquimod cream (5%; Aldara;
3M Pharmaceuticals) on the shaved back. Control mice were treated similarly
with a control vehicle cream. Mice were treated for 6 consecutive days.
Samples were taken 1 day after the last treatment.
Patient Samples
Nonlesional and lesional samples were biopsied only after informed consent to
the patients and following the approval by the Ethics Committee of the Hospital
La Princesa, Madrid, Spain.
Immunohistochemistry and Immunofluorescence
At day 23 of the study, mice were sacrificed and their ears were collected and
cut in half. One half of each ear was processed for paraffin sections, the other
half was embedded in optimal cutting temperature (OCT) compound (Sakkura
Finetek, Torrance, CA), snap-frozen in liquid nitrogen, and 4 mm cryostat sec-
tions were cut. Immunohistological analyses were performed as described
previously by using the following antibodies: CD4 and CD8 (BD Biosciences),
Alexa488- or Alexa594-coupled secondary antibodies (Invitrogen). Hoechst
33342 (Invitrogen) was used for nuclear stains. For paraffin embedding, tissues
were fixed in 3.7% paraformaldehyde (PFA) in PBS (pH 7.2) at 4C overnight.
Before standard dehydration and paraffin infiltration, the tissue was washed in
PBS. Three micrometer sections of formalin-fixed samples were processed
for hematoxylin and eosin stains (H&E) according to standard procedures.
Immunohistochemistry (IHC) with antibodies against anti-mouse keratin 6
and keratin 10 (all from Covance Research Products), S100A8 and S100A9
(both Santa Cruz), Ki67 (Novocastra), and F4-80 (Santa Cruz) was performed
as previously described. Staining for myeloid peroxidase (MPO) was per-
formed as described in Zenz et al. (2005).
The IHC stainings on human paraffin sections were done using anti-human
S100A8-S100A9 (calprotectin, Clone MAC 387, DAKO) and anti-human C3
(F-0201, DAKO) and CD45 (2B11+PD7/26, DAKO) according to the manufac-
turer’s protocol.
The following methods are described in detail in Supplemental Information.
Skin samples were isolated and epidermis was separated from dermis and
analyzed by iTRAQ and for mRNA (quantitative PCRwith reverse transcription)
and protein determination (immunoblotting). Immunocytochemistry was per-
formed on paraformaldehyde fixed paraffin embedded skin sections. Primary
mouse keratinocytes were isolated and cultured. ELISAs were performed ac-
cording to the manufacturer’s protocols. Cell fractionation and ChIP proce-
dures and adoptive bone marrow transfer are described in the Supplemental
Information.
Proteomic Analysis of Nucleosome Extracts
Proteins in nucleosome extracts were digestedwith amodified FASP protocol.
Peptides were separated by online nano-LC and analyzed by electrosprayMS/
MS with a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific). Raw
files were searched against UniProtKB/Swiss-Prot mouse database (release
date: January, 2013 50517 entries) with MASCOT2 as a search engine through1180 Immunity 39, 1171–1181, December 12, 2013 ª2013 Elsevier Inthe Proteome Discoverer (Thermo Scientific) software. Peptides and were
filtered at 1% FDRwith a concatenated database. A more detailed description
of methodology is provided in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, four tables, Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.immuni.2013.11.011.
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